ClinicalTrials.gg
RecruitingNCT06616610Updated Oct 15, 2024

Single-Button Mobility Platform's Effect on Reaction Time and Keystroke Accuracy in Children with Cerebral Palsy

An interventional study of Intervention with the Mobility Platform and Intervention with Traditional Therapy in Cerebral Palsy Infantile, sponsored by University of Seville. Recruiting at 1 site in Spain. Open to participants aged 3 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by University of Seville · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jan 2024, registered Sep 2024).
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
4
Allocation
Randomized
Ages
3 Years to 12 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Cerebral Palsy with a site in Spain — 14 open to participants now, 17 under way, 1 of them phase 3. Cerebral Palsy · Spain.

Planned enrollment
44th of 44
4 · median 32
Started
2024
with 7 others
No phase
37 of 54
11 open now
Primary completion
2025-01
later than 5 of 16 live
Registered
42nd of 54
by date
Lead sponsor
3 of 54
University of Seville

Among the 54 studies in Cerebral Palsy with a site in Spain, this one is the 44th largest by planned enrollment of the 44 interventional ones that give a count, is one of 8 that started in 2024, is one of 37 with no phase, reaches primary completion later than 5 of the 16 other live ones, and was the 42nd registered.

Cerebral Palsy

1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.

Browse Cerebral Palsy studies →

Open to participants now

14 of the 54 studies in Cerebral Palsy with a site in Spain are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.

This study: 3 Years to 12 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Cerebral Palsy with a site in Spain, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine whether the use of a mobility platform can improve response time in children with cerebral palsy.

The primary question it seeks to answer is: Can the use of a mobility platform enhance cognitive development in children with severe disabilities?

Children are randomly assigned to two equal-sized groups: the control group, where participants will continue with their standard therapy, and the intervention group, where participants will use the mobility platform. Researchers will compare outcomes between the two groups.

Participants in the control group will engage in a traditional cause-and-effect therapy, using a video that frequently pauses, requiring them to press an adapted button to continue watching. Participants in the intervention group will use the mobility platform during their sessions. Movement begins when the participant presses the adapted button, and the platform advances, adjusting its direction using sensors to detect obstacles. Once the preset time limit is reached, the platform stops, and the child must press the button again to resume movement. This stop-start process mirrors the cause-and-effect training in the control group.

Read the detailed description

The experimental timeline includes eight weekly sessions, each lasting 30 minutes. Initially, therapists will receive an explanation on how to use the platform and the accompanying configuration application. They will familiarize themselves with it a couple of weeks before the experiment begins. During the sessions, children in the experimental group will use the platform, while those in the control group will continue receiving their traditional therapy.

Researchers will pre-adjust the children\'s interactions to match the platform variables, allowing for meaningful comparisons. Therapists will assess changes in the children's mood or emotional state during each session. To do this, they will calculate the differences between the SAM (Self-Assessment Manikin) tests conducted at the beginning and end of each session. A positive difference in valence indicates an improvement in the participant\'s happiness or positive emotions during the session. Similarly, positive changes in arousal reflect increased calmness or reduced excitation. A seven-item Likert scale will be used for measurement. For instance, if there is a positive change of seven points in valence during a session, the participant moves from a very sad state to a very happy one.

To minimize bias in conducting the experiment and evaluating SAM tests, therapists will be randomly assigned to either the control or intervention groups for each session, while ensuring an equal number of sessions conducted by each therapist. As a result, each therapist will conduct four sessions with the experimental group and four with the control group, with random session assignments.

The dependent variables include reaction time (RT) and the number of incorrect selections (NIS). The mean and standard deviation of these dependent variables allow for the following statistical analyses: Kruskal-Wallis Test: This will be used to compare the dependent variables across groups. SAM Test: It will score the statistically significant differences between the experimental and control groups, with the level of significance set at 5% (p = 0.05). Pearson Regression Analysis: This will identify trends in the dependent variables over time.

The registration procedure is as follows: Variables are collected, transmitted, and stored in a database on a cellphone for later analysis. To achieve this, the investigators used an Open Source Frontend SDK , which enables the deployment of hybrid mobile applications based on web development tools such as HTML, CSS, and JavaScript. The apps run in a browser shell. Several Capacitor plugins were used to manage the database and Bluetooth connectivity, which are essential for data storage and communication. The application interface includes buttons for therapists to enable/disable Bluetooth connections, start/stop recording, and a panic button to halt the platform and abort the experiment. Additionally, users can select their username and group name. Control group therapy involves the use of educational resources that require children to press a button repeatedly. For this group, the investigators chose fairy tale or cartoon videos from YouTube. The specific videos will be tailored to the user's preferences. These videos pause intermittently and require the child to perform an action to resume playback. A microcontroller is used to record time intervals and host an application that detects the child's keystrokes. This data is transmitted via Bluetooth to the same mobile application used for the mobility platform, ensuring synchronization between the experimental and control groups.

03

Conditions studied

  • Cerebral Palsy Infantile

Browse trials for

Keywords

  • Cerebral Palsy
  • Children
  • Reaction Time
  • mobility platform
  • cognitive development
  • GMFCS levels IV-V
  • motor skills
04

Who can participate

Ages eligible
3 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with cerebral palsy
  • Classified as GMFCS level IV or higher, indicating an inability to walk or operate a powered wheelchair.
  • Under 12 years old.
  • Must be affiliated to a center whose facilities guarantee a proper navigation experience

Exclusion criteria

Exclusion Criteria:

  • Inability to act on an actuator (Start button)
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
4 participants (estimated)

Study arms

  • Experimental
    The Experimental Arm

    Participants included in arms are children with the following inclusion criteria: * Diagnosed with cerebral palsy * Classified as GMFCS level IV or higher, indicating an inability to walk or operate a powered wheelchair. * Under 12 years old. * Must be affiliated to a center whose facilities guarantee a proper navigation experience The participants will be randomly assigned to two equal-sized arms: the control arm, in which participants will continue with the traditional therapy, and the experimental arm, where the children will use the platform. The experimental arm receives an intervention (procedure) that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.

    Behavioral: Intervention with the Mobility Platform

  • Active comparator
    The Control Arm

    Participants included in arms are children with the following inclusion criteria: - Diagnosed with cerebral palsy - Classified as GMFCS level IV or higher, indicating an inability to walk or operate a powered wheelchair. - Under 12 years old. - Must be affiliated to a center whose facilities guarantee a proper navigation experience The participants will be randomly assigned to two equal-sized arms: the control arm, in which participants will continue with the traditional therapy, and the experimental arm, where the children will use the platform. The control arm participants continue with their regular therapy. Regular cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.

    Behavioral: Intervention with Traditional Therapy

Interventions

  • BehavioralIntervention with the Mobility Platform

    The experimental arm receives the Intervention with Mobility Platform that is a focus of the study. It aims to analyze the impact of a single-button-operated mobility platform on reaction times and keypress patterns in children with severe disabilities.

  • BehavioralIntervention with Traditional Therapy

    The traditional cause-effect therapies use an animated cartoon video that frequently pauses so that the children have to press an adapted button to continue watching it.

06

What researchers measure

Primary outcomes

  1. Reaction time (RT)

    In the intervention group, RT measures the time elapsed between the platform stopping and the user pressing the button to initiate a new navigation period. In the control group, RT measures the time elapsed between the video pausing and the user pressing the button to continue watching it

    Time frame: From enrollment to the end of treatment at 8 weeks

  2. Number of incorrect selections (NIS)

    NIS represents the number of additional button presses recorded while the Platform is in motion and serves validation purposes. A high value of this variable, consistently maintained over time, suggests that the user is not performing the cause-effect experiment effectively.

    Time frame: From enrollment to the end of treatment at 8 weeks

Secondary outcomes

  1. The Self-Assessment Manikin (SAM) test

    The Self-Assessment Manikin (SAM) test is used to assess the emotional changes in children during the experiment. It comprises a 7-level Likert scale (the scale ranges from 1 to 7) associated with a set of faces displaying various degrees of valence and arousal. Valence reflects how pleasant or unpleasant an emotion. A score of 1 represents the most unpleasant emotion, while a score of 7 represents the most pleasant emotion. Arousal refers to the level of physiological and psychological activation or intensity of an emotional experience. A score of 1 indicates low arousal (low physiological and psychological activation), and a score of 7 indicates high arousal (high activation). Thus, higher scores mean more positive valence (pleasant emotion) and higher arousal (greater intensity).

    Time frame: From enrollment to the end of treatment at 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — IPD used in the results publication.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: From november 2024

Access criteria: Everyone will be able to access all the IPD and all the supporting information. It will be available on It will be available on the Research Data Repository of the University of Seville (IdUS). IdUS is part of the digital infrastructure for open science and offers University of Seville authors a platform to deposit their publications in open access and their research data.

Data sharing details ↗ · idus.us.es

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jan 2025, 12 months after the start.

Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 12 months is close to that.

Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 20, 2024
First posted
Sep 27, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Jan 2025
CompletionEst.
Jun 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06616610
Responsible party
Félix Biscarri Triviño (Head of research group, University of Seville) — Principal investigator
First posted
Sep 27, 2024
Start date
Jan 1, 2024
Primary completion
Jan 2025 (estimated)
Completion
Jun 2025 (estimated)
Last update
Oct 15, 2024

Study contacts

Félix Biscarri, PhD
Contact
fbiscarri@us.es
+34 954552836
Alberto Molina Cantero, PhD
Contact
almolina@us.es
+34 954552787
Alberto Molina Cantero, PhD
principal investigator · University of Seville, Seville, Andalucia, Spain

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion